
Calithera Biosciences, Inc. (NASDAQ:CALA) initiates dosing first patient in the phase 2 clinical trial evaluating its spleen tyrosine kinase (SYK) inhibitor mivavotinib (CB-659) in patients with relapsed/refractory non-germinal center B-cell like (non-GCB) diffuse large B-cell lymphoma (DLBCL).
The phase 2 clinical trial is an open-label multicenter study of mivavotinib monotherapy in patients with relapsed/refractory non-GCB DLBCL.